Risk of Group 2 Pulmonary Hypertension in Newly Diagnosed Heart Failure: An EHR-Based Cohort Analysis
Group 2 pulmonary hypertension (PH) worsens heart failure (HF) outcomes, but its incidence by HF subtype is unclear. In 17,212 UPMC HF patients, PH was initially more common in HFrEF but surpassed by HFpEF after two years. Women had higher PH incidence, with HFpEF increasing PH risk by 23% in women but not in men. These findings highlight the need for PH screening in all HF patients, especially those with HFpEF and women. Integrating PH risk stratification into HF care may support earlier intervention, guide treatment decisions, and improve long-term outcomes in this growing, high-risk population.
Authors
- Manling Zhang (ORCID: https://orcid.org/0000-0003-2689-1465)
- Flora Sam (ORCID: https://orcid.org/0000-0001-8442-9362)
- Zeshui Yu (ORCID: https://orcid.org/0009-0002-4535-8770)
- Ning Feng (ORCID: https://orcid.org/0000-0003-3639-3128)
- Yu Chen (ORCID: https://orcid.org/0000-0001-8484-040X)
- Yuqing Chen (ORCID: https://orcid.org/0000-0001-7857-3106)
- Lirong Wang (ORCID: https://orcid.org/0000-0002-9092-6282)
Institutions
- Eli Lilly (United States) (US)
- University of Pittsburgh (US)
Publication Details
- Journal
- medRxiv
- Published
- 2025-12-09
- DOI
- https://doi.org/10.64898/2025.12.03.25341274
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- University of Pittsburgh
- National Institutes of Health
- Center for Research Computing, University of Pittsburgh